Health Care • Biotechnology: Pharmaceutical Preparations
$8.91 ▲ +0.04
(+0.45%)
MKT CAP: $264.1M • VOL: 268.2K
52W L $2 52W H $24
QTTB // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $53.7M | $0 | $1.2M |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $16.9M | -$66.1M | -$48.3M |
| Operating Margin % | 31.5% | — | -80.0% |
| Net Income (GAAP) | $29.8M | -$47.7M | -$53.7M |
| EBITDA (Normalized) | $16.9M | -$66.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$33.5M | -$67.7M | -$18.7M |
| Capital Expenditures (CapEx) | $0 | $75.0K | — |
| Free Cash Flow (FCF) | -$33.5M | -$67.8M | -$18.7M |
| FCF Margin % | -62.4% | — | -80.0% |
| Return on Invested Capital (ROIC %) | 95.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $48.3M | $78.0M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $42.0M | $5.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR QTTB.